Taku Fujimura

Lecturer

Tohoku University graduate school of medicine

Japan

Research Interests

Explore related searches

Professors in Japan

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Taku Fujimura is a Lecturer at Tohoku University Graduate School of Medicine in Japan. His research focuses on skin malignancies, particularly the role of tumor microenvironments in immunotherapy and the therapeutic implications of plasminogen activator inhibitor-1. Recent articles authored by him delve into taxane-induced scleroderma, advanced melanoma treatments, and clinical guidelines for cutaneous angiosarcoma.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (9)

Toshiya Takahashi

Assistant Professor

Tohoku University Hospital

JAPAN

View details

Takehiro Takahashi

Senior Lecturer

Tohoku University

JAPAN

View details

Yusuke Muto

Tohoku University

JAPAN

View details

Yoji Hirai

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

JAPAN

View details

Yoshihide Asano

Professor

Tohoku University graduate school of medicine

JAPAN

View details

Jun Yamamoto

Tohoku University

JAPAN

View details

Sayaka Shibata

Graduate School of Medicine, The University of Tokyo

JAPAN

View details

Kazuki Hashimoto

Tohoku University

JAPAN

View details

Takashi Yahata

Professor

Tokai University School of Medicine

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Taku Fujimura

Research Interests

Explore related searches

Contact this professor

About

Articles (30)

A Case of Taxane‐Induced Scleroderma Presenting in a Unilateral Upper Limb and a Literature Review

Plasminogen Activator Inhibitor-1 in Skin Malignancies: Therapeutic Implications of Its Inhibition

The significance of tumor microenvironment for immunotherapy in melanoma and non-melanoma skin cancer

An Open‐Label, Multicenter, Phase II Study of Bexarotene in Patients with Adult T‐Cell Leukemia/Lymphoma

Diffuse Large B‐Cell Lymphoma Arising in Mycosis Fungoides With Large‐Cell Transformation

Secondary Publication of Japanese Dermatological Association Guidelines: Clinical Questions of Guidelines for Cutaneous Angiosarcoma 2025

Recent Advances in Immunotherapy for Melanoma: Perspectives on the Development of Novel Treatments: A Mini Review

Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment

Significance of PAI-1 on the development of skin cancer: optimal targets for cancer therapies

Impact of Hyaluronic Acid on the Cutaneous T-Cell Lymphoma Microenvironment: A Novel Anti-Tumor Mechanism of Bexarotene

The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study

Analysis of surgical margins and prognostic factors in dermatofibrosarcoma protuberans after wide local excision: A multicenter study of 116 Japanese patients

Decreased serum levels of IL-4 correlate with the efficacy of the PAI-1 inhibitor TM5614 in patients with malignant melanoma refractory to anti-PD-1 antibodies: post hoc study of TM5614-MM trial

Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30‐positive cutaneous T‐cell lymphoma

Three-Year Analysis of Adjuvant Therapy in Postoperative Melanoma including Acral and Mucosal Subtypes

A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial

Vogt‐Koyanagi‐Harada disease‐like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA‐DRB1*04

Radiation‐induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case report

Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel‐resistant cutaneous angiosarcoma: Phase II study protocol

Possible effects of plasminogen activator inhibitor‐1 on promoting angiogenesis through matrix metalloproteinase 9 in advanced mycosis fungoides

LL-37 Might Promote Local Invasion of Melanoma by Activating Melanoma Cells and Tumor-Associated Macrophages

Papular interstitial elastolytic giant cell granuloma concomitant with lichen amyloidosus in a type II diabetes patient

The significance of M1‐polarized CD163+ macrophages in acute graft‐versus‐host disease (GVHD): Possible mechanisms of GVHD in the development of skin lesions

Treatment for taxane‐resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

Cutaneous angiosarcoma treated with taxane‐based chemoradiotherapy: A multicenter study of 90 Japanese cases

Plasminogen activating inhibitor‐1 promotes angiogenesis in cutaneous angiosarcomas

Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real‐world case series

A pediatric case of corticosteroid‐resistant erosive pustular dermatosis of scalp‐like alopecia treated successfully with oral indomethacin, doxycycline, and topical tacrolimus

Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy

Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers

Collaborators (9)

Toshiya Takahashi

Takehiro Takahashi

Yusuke Muto

Yoji Hirai

Yoshihide Asano

Jun Yamamoto

Sayaka Shibata

Kazuki Hashimoto

Takashi Yahata

Make your next move.